Literature DB >> 1316409

Mycoplasma contamination in human leukemia cell lines. II. Elimination with various antibiotics.

C C Uphoff1, S M Gignac, H G Drexler.   

Abstract

19 suspension cell lines were treated with antibiotics for elimination of chronic contamination with mycoplasma. We compared the efficiency, cytotoxicity and cross-resistance of the commercially available antibiotics MRA (Mycoplasma Removal Agent, a quinolone derivative and DNA gyrase inhibitor), Ciprobay (ciprofloxacin, also a quinolone derivative and DNA gyrase inhibitor), and BM-cyclin (a combination of tiamulin, a pleuromutilin derivative, and minocycline, a tetracycline derivative, both inhibitors of protein synthesis on ribosomes). Contaminants were eliminated in all 19 cell lines by BM-Cyclin. Only 74% of the cell lines were cleared of contamination by both MRA and Ciprobay. Successful treatment was monitored by three mycoplasma detection assays. Cross-resistance was noted between MRA and Ciprobay in four of the five cell lines not cleared by either reagent. This resistance could, however, be overcome by consecutive exposure to BM-cyclin. Employed at the recommended concentrations, the antibiotics did not cause marked cytotoxicity, but the growth of the cells was affected to various degrees by some antibiotics. The elimination of mycoplasma from chronically contaminated cell lines is an effective alternative to other treatment protocols, but is cost-intensive and time-consuming; lasting damaging effects of the treatments on the eukaryotic cells cannot be excluded. Long-term post-treatment monitoring is mandatory, since contaminants may only be suppressed and then recur.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316409     DOI: 10.1016/s0022-1759(12)80048-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Rapid authentication of animal cell lines using pyrolysis mass spectrometry and auto-associative artificial neural networks.

Authors:  R Goodacre; D J Rischert; P M Evans; D B Kell
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Application of surfactin for mycoplasma inactivation in virus stocks.

Authors:  E Nissen; G Pauli; J Vater; D Vollenbroich
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-06       Impact factor: 2.416

3.  Comparative antibiotic eradication of mycoplasma infections from continuous cell lines.

Authors:  Cord C Uphoff; Hans G Drexler
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-02       Impact factor: 2.416

4.  Antimycoplasma properties and application in cell culture of surfactin, a lipopeptide antibiotic from Bacillus subtilis.

Authors:  D Vollenbroich; G Pauli; M Ozel; J Vater
Journal:  Appl Environ Microbiol       Date:  1997-01       Impact factor: 4.792

5.  PCR-based detection and eradication of mycoplasmal infections from various mammalian cell lines: a local experience.

Authors:  Vahid Molla Kazemiha; Mohammad Ali Shokrgozar; Mohammad Reza Arabestani; Morteza Shojaei Moghadam; Shahram Azari; Susan Maleki; Amir Amanzadeh; Mahmood Jeddi Tehrani; Fazel Shokri
Journal:  Cytotechnology       Date:  2010-02-06       Impact factor: 2.058

6.  Treatment of mycoplasma contamination in a large panel of cell cultures.

Authors:  H G Drexler; S M Gignac; Z B Hu; A Hopert; E Fleckenstein; M Voges; C C Uphoff
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-05       Impact factor: 2.416

7.  Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention.

Authors:  Hans G Drexler; Cord C Uphoff
Journal:  Cytotechnology       Date:  2002-07       Impact factor: 2.058

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.